Hematology TimesEZH2 inhibitor proves active in rel/ref NHLJune 23, 2015Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesCAR T-cell therapy seems feasible for NHL, MMJune 11, 2015Lymphoma & Plasma Cell DisordersMultiple MyelomaNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesPrenatal test can detect lymphoma in mothersJune 8, 2015Lymphoma & Plasma Cell DisordersHodgkin LymphomaFollicular Lymphoma
Hematology TimesDrug prolongs PFS in indolent, refractory NHLJune 2, 2015Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Oncology PracticeGADOLIN: Combination improves PFS in rituximab-refractory indolent NHLMay 30, 2015Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesSusceptibility to 2nd cancers in WM/LPL survivorsApril 30, 2015Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLHodgkin LymphomaNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesInhibitor gets orphan designation for DLBCLApril 8, 2015Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesVitamin D levels linked to outcomes in FLApril 1, 2015Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesPesticides may cause NHL, other cancersMarch 25, 2015Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesMaintenance prolongs PFS, not OS, in relapsed CLLJanuary 7, 2015Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesApproach can cure even high-risk FL, study suggestsDecember 23, 2014Lymphoma & Plasma Cell DisordersTransplantationNon-Hodgkin LymphomaFollicular Lymphoma
Hematology NewsAutologous stem-cell transplant boosts survival in sequential transformed indolent lymphomaDecember 11, 2014Aggressive LymphomasFollicular Lymphoma
Hematology TimesAntibody shows activity in relapsed/refractory NHLDecember 11, 2014Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology NewsOfatumumab maintenance halves risk of progression in relapsed CLLDecember 7, 2014CLLTransfusion MedicineFollicular Lymphoma
Hematology TimesDrug gets orphan designation for MM & CLL/SLLDecember 3, 2014Lymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyNon-Hodgkin LymphomaFollicular Lymphoma
